Cary J. Claiborne - 07 Apr 2026 Form 4 Insider Report for ADIAL PHARMACEUTICALS, INC. (ADIL)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ADIL
Reported as of: 07 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Apr 2026, 17:00:03 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ John Martin, Attorney-in-fact for Cary J. Claiborne

Key filing fact

Cary J. Claiborne filed Form 4 for ADIAL PHARMACEUTICALS, INC. (ADIL) on 09 Apr 2026.

Key facts

This page summarizes Cary J. Claiborne's Form 4 filing for ADIAL PHARMACEUTICALS, INC. (ADIL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Apr 2026, 17:00.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001370930 Primary reporting owner

Claiborne Cary J

Relationship: Chief Executive Officer, Director
Address: 4870 SADLER ROAD, STE 300, GLEN ALLEN
Signature: /s/ John Martin, Attorney-in-fact for Cary J. Claiborne
Signature date: 09 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADIL transaction

Common Stock

Award

Transaction value
Shares: +37,985
Change %: +1562%
Price: $0.000000^*
Shares after: 40,417
Date: 07 Apr 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.